Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadia Dallera

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Clinical Journal of the American Society of Nephrology : CJASN|December 19, 2009
Lack of association between dialysis modality and outcomes in atheroembolic renal diseasePietro Ravani, Rossella Gaggi, Cristiana Rollino, et al.
Kidney International|January 8, 2015
Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosisGina Gregorini, Claudia Izzi, Pietro Ravani, et al.
BMJ Open|December 7, 2019
Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trialFrancesco Scolari, Nadia Dallera, Loreto Gesualdo, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 14, 2011
Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trialPietro Ravani, Alberto Magnasco, Alberto Edefonti, et al.
Journal of the American Society of Nephrology : JASN|March 2, 2021
Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized TrialFrancesco Scolari, Elisa Delbarba, Domenico Santoro, et al.
Nature Genetics|October 13, 2014
Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogensKrzysztof Kiryluk, Yifu Li, Francesco Scolari, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Clinical Journal of the American Society of Nephrology : CJASN|December 19, 2009
Lack of association between dialysis modality and outcomes in atheroembolic renal diseasePietro Ravani, Rossella Gaggi, Cristiana Rollino, et al.
Kidney International|January 8, 2015
Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosisGina Gregorini, Claudia Izzi, Pietro Ravani, et al.
BMJ Open|December 7, 2019
Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trialFrancesco Scolari, Nadia Dallera, Loreto Gesualdo, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 14, 2011
Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trialPietro Ravani, Alberto Magnasco, Alberto Edefonti, et al.
Journal of the American Society of Nephrology : JASN|March 2, 2021
Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized TrialFrancesco Scolari, Elisa Delbarba, Domenico Santoro, et al.
Nature Genetics|October 13, 2014
Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogensKrzysztof Kiryluk, Yifu Li, Francesco Scolari, et al.
Pageof 2